By Andrea Figueras Roche said that the European Commission approved Tecentriq SC, a cancer immunotherapy subcutaneous injection for multiple cancer types. The Swiss pharmaceutical company said Tuesday that…
Read more Roche's Cancer Injection Tecentriq SC Gets European Commission ApprovalBy Mauro Orru Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast cancer. The Swiss pharmaceutical company said Tuesday…
Read more Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage StudyBristol Myers Squibb Co. said Sunday it will buy Mirati Therapeutics Inc. in a deal valued at up to $5.8 billion. The pharmaceutical giant announced it will pay…
Read more Bristol Myers Squibb to buy Mirati Therapeutics in deal worth up to $5.8 billionBy David Sachs Roche said Friday that its Alecensa drug demonstrated the ability to reduce recurrence of lung cancer for patients in the early stage of the disease.…
Read more Roche Lung Cancer Drug Shows Promise in Phase 3 TrialLast November, FDA inspectors found almost farcical conditions when they inspected an Indian manufacturing plant that supplies medical drugs to the United States. The plant, owned by Intas…
Read more The Cancer-Drug Shortage Is DifferentBy Anthony O. Goriainoff AstraZeneca said Thursday that its and MSD’s Lynparza cancer treatment had been approved in the U.S. for the treatment of metastatic castration-resistant prostate cancer,…
Read more AstraZeneca Says US Approved Lynparza as a Prostate Cancer TreatmentPfizer Agrees to Buy Seagen for $43 Billion Source link
Read more Pfizer Agrees to Buy Seagen for $43 Billion
